Blogs

Sarjen’s PvNET breaks the monopoly- A reputed Indian CRO opted Sarjen’s PvNET over Oracle based safety database

13th May, 2015

by

We live in a competitive era where only change is constant. Sarjen is proud to announce that Sarjen’s PvNET was picked as a regulatory compliant safety database over one of the market competitors. We consider it to our credit and put across the points that stood strong in our favor.

Sarjen's PvNET breaks the monopoly- A reputed Indian CRO opted Sarjen's 
PvNET over Oracle based safety database

Few points that have indeed worked as table turners are discussed here:

  • Sarjen’s PvNET embraces Company’s internal policies: Sarjen’s PvNET understands and acknowledges the fact that Pharmacovigilance service providers have differing internal policies and procedures to meet the regional and global regulatory expectations. Sarjen’s PvNET embraces this fact and is open to all pragmatic changes with appropriate rationale.
  • Literature monitoring tool: Literature automation in Sarjen’s PvNET is that feather of Sarjen’s PvNET cap that invites accolades from the users. Any/all users who are currently facing challenges in this area will but endorse this fact once they access the LAM (Literature automation module) feature.
  • One-stop solution to Generic product PV service providers/CROs/KPOs/BPOs/SPOs: Sarjen’s PvNET has gauged the huge gap that lies between the flooded generic market and their compliance to PV regulations. Most of the database providers existent in the market have solutions for innovator’s products but are incompatible or non-affordable to generic sector.

Sarjen’s PvNET is the required answer for Generic industries for whom regulatory safety compliance would no more remain a non-complied encumbrance.

  • Competitive pricing model: The current market of database providers are too expensive a model to be afforded by SMEs and a budgetary bolt for the biggies.

Sarjen’s PvNET stands out to deliver a time-tested software for catering to 360° pharmacovigilance requirements of course in consensus with international standards adhered!

For regular Pharmacovigilance updates, connect with us on LinkedIn

Contact Us for more details

Back to Top